RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,530,000 | -43.9% | 200,000 | -45.2% | 0.01% | -57.9% |
| Q2 2023 | $2,726,550 | -2.7% | 365,000 | -13.1% | 0.02% | -29.6% |
| Q1 2023 | $2,801,400 | -9.2% | 420,000 | +5.0% | 0.03% | -50.0% |
| Q4 2022 | $3,084,000 | -3.4% | 400,000 | +33.3% | 0.05% | +50.0% |
| Q3 2022 | $3,192,000 | +30.7% | 300,000 | 0.0% | 0.04% | +24.1% |
| Q2 2022 | $2,442,000 | +13.7% | 300,000 | 0.0% | 0.03% | +11.5% |
| Q1 2022 | $2,148,000 | -55.2% | 300,000 | +7.1% | 0.03% | -50.0% |
| Q4 2021 | $4,796,000 | -21.4% | 280,000 | +5.7% | 0.05% | -16.1% |
| Q3 2021 | $6,098,000 | -33.8% | 265,000 | +5.0% | 0.06% | -18.4% |
| Q2 2021 | $9,216,000 | – | 252,500 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |